{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:52:37Z","timestamp":1788137557332,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024B03J1281"],"award-info":[{"award-number":["2024B03J1281"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3502803"],"award-info":[{"award-number":["2023YFC3502803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022B1515020079"],"award-info":[{"award-number":["2022B1515020079"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574681"],"award-info":[{"award-number":["82574681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81961128028"],"award-info":[{"award-number":["81961128028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ethnopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jep.2026.121723","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:27:05Z","timestamp":1776443225000},"page":"121723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A preliminary exploratory clinical study of Xiao-Chai-Hu-Tang co-administered with irinotecan-based chemotherapy in advanced colorectal cancer"],"prefix":"10.1016","volume":"367","author":[{"given":"Jialin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runze","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenyuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-5247","authenticated-orcid":false,"given":"Lijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.2042-7158.1994.tb03756.x","article-title":"Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats","volume":"46","author":"Akao","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"issue":"15_Suppl. l","key":"10.1016\/j.jep.2026.121723_bib2","article-title":"A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors","volume":"28","author":"Alsamarai","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jep.2026.121723_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22217","article-title":"Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC\/MS\/MS: application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients","volume":"32","author":"Atasilp","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"10.1016\/j.jep.2026.121723_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/1078-0432.CCR-12-1800","article-title":"A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer","volume":"19","author":"Berlin","year":"2013","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"Suppl. 4","key":"10.1016\/j.jep.2026.121723_bib5","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jep.2026.121723_bib6","first-page":"2688","article-title":"Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer","volume":"14","author":"Canal","year":"1996"},{"issue":"4","key":"10.1016\/j.jep.2026.121723_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","article-title":"Clinical pharmacokinetics of irinotecan","volume":"33","author":"Chabot","year":"1997","journal-title":"Clin. Pharmacokinet."},{"issue":"47","key":"10.1016\/j.jep.2026.121723_bib8","doi-asserted-by":"crossref","first-page":"19143","DOI":"10.1073\/pnas.1319123110","article-title":"Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)","volume":"110","author":"Chen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/dmd.112.046276","article-title":"Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone","volume":"41","author":"Choi","year":"2013","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"issue":"7","key":"10.1016\/j.jep.2026.121723_bib10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2018.1080","article-title":"Association of patient sex with chemotherapy-related toxic effects: a retrospective analysis of the PETACC-3 trial conducted by the EORTC Gastrointestinal group","volume":"4","author":"Cristina","year":"2018","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.jep.2026.121723_bib11","first-page":"2355","article-title":"Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer","volume":"30","author":"Czejka","year":"2010","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.jep.2026.121723_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101389","article-title":"Does chemotherapy-induced gastrointestinal mucositis affect the bioavailability and efficacy of anti-infective drugs?","volume":"9","author":"da Silva Ferreira","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.jep.2026.121723_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1745-7254.2008.00850.x","article-title":"Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu- tang across human intestinal Caco-2 cell monolayers","volume":"29","author":"Dai","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jep.2026.121723_bib14","article-title":"Preventive effects of a Chinese herbal formula, Shengjiang Xiexin decoction, on irinotecan-induced delayed-onset diarrhea in rats. Evidence-based complementary and alternative medicine","volume":"2017","author":"Deng","year":"2017","journal-title":"eCAM"},{"issue":"1","key":"10.1016\/j.jep.2026.121723_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-009-1008-7","article-title":"Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors","volume":"65","author":"Denlinger","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jep.2026.121723_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121767","article-title":"Metabolic profiles of Xiao Chai Hu Tang in mouse plasma, bile and urine by the UHPLC-ESI-Q-TOF\/MS technique","volume":"1128","author":"Du","year":"2019","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"issue":"9","key":"10.1016\/j.jep.2026.121723_bib17","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1999.17.9.2901","article-title":"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer","volume":"17","author":"Ducreux","year":"1999","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"1\u20132","key":"10.1016\/j.jep.2026.121723_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000111083","article-title":"Phase II clinical trial for prevention of delayed diarrhea with cholestyramine\/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma","volume":"72","author":"Flieger","year":"2007","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.jep.2026.121723_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/psp4.12047","article-title":"Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers","volume":"4","author":"Gufford","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib20","first-page":"231","article-title":"Quantification of Panax notoginseng saponins metabolites in rat plasma with in vivo gut microbiota-mediated biotransformation by HPLC-MS\/MS","volume":"17","author":"Guo","year":"2019","journal-title":"Chin. J. Nat. Med."},{"issue":"4","key":"10.1016\/j.jep.2026.121723_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1745-7254.2006.00303.x","article-title":"Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models","volume":"27","author":"Han","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jep.2026.121723_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119790","article-title":"Huangqin decoction alleviated irinotecan-induced diarrhea by inhibiting endoplasmic reticulum stress through activating AMPK\/mTOR-mediated autophagy","volume":"347","author":"He","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-009-1051-4","article-title":"Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy","volume":"65","author":"Horita","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.taap.2006.05.020","article-title":"St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis","volume":"216","author":"Hu","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.jep.2026.121723_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3937\/kampomed.53.639","article-title":"Pathogenesis and treatment of Shao yang disease learned in the Shang Han Lun","volume":"53","author":"Kaneko","year":"2002","journal-title":"Kampo Med."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/COC.0b013e3181a650d4","article-title":"A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer","volume":"33","author":"Kim","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jep.2026.121723_bib28","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41598-025-34936-x","article-title":"Comparative analysis of sex-based, vendor-based, and species differences in cytochrome P450 metabolism","volume":"16","author":"Kinatukara","year":"2026","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.imr.2020.100480","article-title":"Could herbal medicine (Soshihotang) be a new treatment option for COVID-19?: a narrative review","volume":"9","author":"Kwon","year":"2020","journal-title":"Integr. Med. Res."},{"key":"10.1016\/j.jep.2026.121723_bib30","article-title":"Xiao chai Hu Tang for peptic ulcers: a systematic review and meta-analysis of randomized controlled trials","volume":"2021","author":"Li","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med. : eCAM"},{"issue":"9","key":"10.1016\/j.jep.2026.121723_bib31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.bjc.6603095","article-title":"A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients","volume":"94","author":"Mabro","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jep.2026.121723_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2023.04.109","article-title":"Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: a new concept","volume":"665","author":"Martha","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6600447","article-title":"Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38","volume":"87","author":"Mathijssen","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jep.2026.121723_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00280-003-0585-0","article-title":"Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer","volume":"51","author":"Mori","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jep.2026.121723_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00265854","article-title":"Necrotising colitis with perforation in diarrhoic patients treated with loperamide","volume":"40","author":"Olm","year":"1991","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jep.2026.121723_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122875","article-title":"Exploring the potential of human intestinal organoids: applications, challenges, and future directions","volume":"352","author":"Parente","year":"2024","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00280-005-0166-5","article-title":"Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen","volume":"58","author":"Poujol","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.jep.2026.121723_bib38","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdt056","article-title":"Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study","volume":"24","author":"Schultheis","year":"2013","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdp489","article-title":"A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors","volume":"21","author":"Sharma","year":"2010","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.jep.2026.121723_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"7","key":"10.1016\/j.jep.2026.121723_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2174\/1568009618666181029153255","article-title":"Xiao-Chai-Hu-Tang (XCHT) intervening Irinotecan's disposition: the potential of XCHT in alleviating Irinotecan-Induced diarrhea","volume":"19","author":"Sun","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jep.2026.121723_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jchromb.2015.09.004","article-title":"Simultaneous determinations of 17 marker compounds in Xiao-Chai-Hu-Tang by LC-MS\/MS: application to its pharmacokinetic studies in mice","volume":"1003","author":"Sun","year":"2015","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jep.2026.121723_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115032","article-title":"Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: critical role of gut Ugt","volume":"398","author":"Sun","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.jep.2026.121723_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104542","article-title":"Organoid-derived intestinal epithelial cells are a suitable model for preclinical toxicology and pharmacokinetic studies","volume":"25","author":"Takahashi","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.jep.2026.121723_bib45","article-title":"Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4\/MyD88 pathway prior to the onset of diarrhea","volume":"166","author":"Tao","year":"2022"},{"issue":"15","key":"10.1016\/j.jep.2026.121723_bib46","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.jep.2026.121723_bib47","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1124\/dmd.111.041897","article-title":"Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1\u221728 polymorphism","volume":"39","author":"Trdan Lusin","year":"2011","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"issue":"4","key":"10.1016\/j.jep.2026.121723_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3253","article-title":"A novel NCI-H69V small cell lung cancer functional mini-tumor model for future treatment screening applications","volume":"38","author":"van der Merwe","year":"2022","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jep.2026.121723_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155040","article-title":"Insight into the mechanism of Xiao-Chai-Hu-Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut \u03b2-GUS","volume":"120","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"9","key":"10.1016\/j.jep.2026.121723_bib51","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/jps.22568","article-title":"First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics","volume":"100","author":"Wu","year":"2011","journal-title":"J. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.jep.2026.121723_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/mcp.2002.126741","article-title":"Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea","volume":"72","author":"Xie","year":"2002","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.jep.2026.121723_bib53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lfs.2005.04.072","article-title":"Absorption and enterohepatic circulation of baicalin in rats","volume":"78","author":"Xing","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.jep.2026.121723_bib54","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.2147\/OTT.S104981","article-title":"Survival benefit and safety of the combinations of FOLFOXIRI \u00b1 bevacizumab versus the combinations of FOLFIRI \u00b1 bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis","volume":"9","author":"Xu","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jep.2026.121723_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.628358","article-title":"Total flavonoids of Glycyrrhiza uralensis alleviates irinotecan-induced colitis via modification of Gut Microbiota and fecal metabolism","volume":"12","author":"Yue","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jep.2026.121723_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/529458","article-title":"Current understanding on antihepatocarcinoma effects of xiao chai hu tang and its constituents","volume":"2013","author":"Zheng","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med. : eCAM"},{"issue":"9","key":"10.1016\/j.jep.2026.121723_bib57","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s11095-024-03755-6","article-title":"Fecal SN-38 content as a surrogate predictor of intestinal SN-38 exposure and associated Irinotecan-induced severe delayed-onset diarrhea by a novel use of the spectrofluorimetric method","volume":"41","author":"Zheng","year":"2024","journal-title":"Pharm. Res."}],"container-title":["Journal of Ethnopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874126005751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874126005751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:59:58Z","timestamp":1778752798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378874126005751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S0378874126005751"],"URL":"https:\/\/doi.org\/10.1016\/j.jep.2026.121723","relation":{},"ISSN":["0378-8741"],"issn-type":[{"value":"0378-8741","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A preliminary exploratory clinical study of Xiao-Chai-Hu-Tang co-administered with irinotecan-based chemotherapy in advanced colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Ethnopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jep.2026.121723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121723"}}